Exact Sciences Corp. reported fourth‑quarter and full‑year 2025 results that set new company records. Revenue rose to $878 million in the quarter and $3.25 billion for the year, beating consensus estimates of $860.9 million and $3.246 billion, respectively. The company posted a net loss of $86 million in the quarter and $208 million for the year, a dramatic improvement from the $864.6 million and $1.03 billion losses reported in 2024. Earnings per share were –$0.21 for the quarter and –$0.21 for the year, missing the consensus of $0.08 and $0.08, respectively.
Revenue growth was driven by a 26% year‑over‑year increase in the Screening segment, which generated $695 million in the quarter and $2.53 billion for the year, and a 14% rise in Precision Oncology, which produced $183 million in the quarter and $717 million for the year. The Screening segment’s expansion reflects continued uptake of the flagship Cologuard test and the launch of new blood‑based tests, while the Precision Oncology segment benefited from the Oncodetect molecular residual disease test and additional validation data for the Oncoguard liver blood test.
The company also highlighted several product milestones. Oncodetect was launched on April 22 2025 and received additional validation data on November 7 2025, with a breast‑cancer substudy presented in December 2025. Oncoguard liver received pivotal validation results from the ALTUS study on November 7 2025. In addition, the Hart‑Scott‑Rodino Act clearance for the Freenome blood‑based colorectal cancer screening license was announced on November 10 2025, removing a regulatory hurdle that had delayed the company’s entry into blood‑based screening.
Analysts had expected revenue of $860.9 million for the quarter, so Exact Sciences beat revenue estimates by $17.1 million, or 2.0%. However, the company missed earnings expectations by $0.29 per share, as the loss of $0.21 per share fell short of the consensus of $0.08. The revenue beat was largely driven by the strong performance of the Screening segment, while the earnings miss was attributable to the company’s continued investment in product development and the higher cost of the new tests, which offset the gains from increased sales.
Exact Sciences did not provide new forward guidance for 2026, but the company confirmed that it will not hold a Q4 conference call because of the pending acquisition by Abbott Laboratories, which is expected to close in the second quarter of 2026. The acquisition is anticipated to provide additional resources and market reach for the company’s expanding diagnostic portfolio.
CEO Kevin Conroy said, 'In 2025 the Exact Sciences team delivered on our mission by screening more people than ever before, helping guide more personalized treatment decisions, and successfully launching three new tests.' He added, 'These defining milestones show what the Exact Sciences team can achieve through a relentless focus on our mission and a dedication to improving the lives of patients. As we look to the future, momentum continues to build. Our core products are driving strong growth, our portfolio is expanding, and we are uniquely positioned to drive lasting change in the way cancer is found and treated globally.' Conroy also noted, 'The exclusive license expands the Company's leadership in cancer screening by adding blood‑based CRC screening options to its portfolio.'
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.